新型双功能FAP/乏氧PET示踪剂[68Ga]Ga-DOTA-NI-FAPI-04首次人体研究
该研究在50例患者中头对头比较[68Ga]Ga-DOTA-NI-FAPI-04与[68Ga]Ga-DOTA-FAPI-04 PET/CT,前者在原发性肿瘤、淋巴结转移、骨转移和肝转移中摄取均显著更高(P<0.05或P<0.001),且HIF-1α表达与ΔSUVmax正相关(r=0.528,P=0.011),提示乏氧敏感基团有助于提高肿瘤检出。
要点
- [68Ga]Ga-DOTA-NI-FAPI-04有效吸收剂量为1.95E-02 mSv/MBq
- 在原发性肿瘤、淋巴结、骨和肝转移中摄取显著高于[68Ga]Ga-DOTA-FAPI-04
- HIF-1α表达与ΔSUVmax正相关(r=0.528,P=0.011),增强乏氧病灶显像
核心结论
- [68Ga]Ga-DOTA-NI-FAPI-04较[68Ga]Ga-DOTA-FAPI-04显著提高肿瘤摄取和滞留,尤其增强乏氧病灶可视化,乏氧敏感基团可能在肿瘤检测中起重要作用。
- 建议进一步开展[177Lu]Lu-DOTA-NI-FAPI-04人体研究以探索其临床应用。
研究设计与样本
- 首次人体研究,50例患者在一周内配对接受[68Ga]Ga-DOTA-NI-FAPI-04与[68Ga]Ga-DOTA-FAPI-04 PET/CT。
- 其中4例接受系列动态[68Ga]Ga-DOTA-NI-FAPI-04 PET扫描用于剂量学评估,其余患者在60分钟和120分钟进行扫描。
- 计算[68Ga]Ga-DOTA-NI-FAPI-04减去[68Ga]Ga-DOTA-FAPI-04 PET/CT的SUVmax差值(ΔSUVmax)进行分析。
- 对22例原发肿瘤进行FAP和HIF-1α免疫组化检测。
主要发现
- [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT的有效吸收剂量为1.95E-02 mSv/MBq。
- 肿瘤摄取表现为快速摄取和稳定值(3至120分钟平均SUVmax 11.6-13.0)。
- [68Ga]Ga-DOTA-NI-FAPI-04在原发性肿瘤(P<0.05)、淋巴结转移(P<0.001)、骨转移(P<0.001)和肝转移(P<0.05)中摄取显著高于[68Ga]Ga-DOTA-FAPI-04 PET/CT。
- FAP表达与HIF-1α表达相关(r=0.661,P<0.001),HIF-1α表达与ΔSUVmax呈正相关(r=0.528,P=0.011)。
临床怎么用
- [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT可能在乏氧病灶检测中提供优于[68Ga]Ga-DOTA-FAPI-04的显像效果。
- 该示踪剂有效吸收剂量为1.95E-02 mSv/MBq,可供临床剂量评估参考。
- 乏氧相关标志物HIF-1α与ΔSUVmax正相关,提示SUVmax差值可能反映乏氧程度。
局限性
- 研究为首次人体研究,样本量50例,部分分析(如免疫组化)仅纳入22例原发肿瘤。
- 试验为回顾性注册(注册时间2024年11月14日,回顾性注册)。
- 原文未报告长期随访或疗效终点数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies have demonstrated that [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04, a bivalent agent containing an extra hypoxia-sensitive 2-nitroimidazole (NI) group, exhibited favorable tumor binding affinity and improved tumor uptake and retention than [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-04. This study aims to further investigate the value of clinical application for [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT via a direct head-to-head comparison with [68Ga]Ga-DOTA-FAPI-04. METHODS: A total of 50 patients underwent paired [68Ga]Ga-DOTA-NI-FAPI-04 and [68Ga]Ga-DOTA-FAPI-04 PET/CT within 1 week interval. Among these, four patients underwent serial dynamic [68Ga]Ga-DOTA-NI-FAPI-04 PET scans for dosimetry evaluation, and the others underwent scans at 60 min and 120 min. Additionally, we calculated the SUVmax differences (ΔSUVmax) by [68Ga]Ga-DOTA-NI-FAPI-04 minus [68Ga]Ga-DOTA-FAPI-04 PET/CT for further analysis. Immunohistochemistry for FAP and hypoxia-inducible factor-1 alpha (HIF-1α) was performed in 22 primary tumors. RESULTS: The effective absorbed dose of [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT was calculated as 1.95E-02 mSv/MBq. Tumor uptake of [68Ga]Ga-DOTA-NI-FAPI-04 showed rapid uptake and steady values (average SUVmax 11.6-13.0 from 3 to 120 min). [68Ga]Ga-DOTA-NI-FAPI-04 exhibited significantly higher uptake in tumor lesions compared to [68Ga]Ga-DOTA-FAPI-04 PET/CT, particularly in primary tumors (P < 0.05), nodal metastases (P < 0.001), bone metastases (P < 0.001), and liver metastases (P < 0.05). That of FAP expression was correlated with that of HIF-1α (r = 0.661, P < 0.001), and the expression of HIF-1α showed a positive correlation with ΔSUVmax (r = 0.528, P = 0.011). CONCLUSION: [68Ga]Ga-DOTA-NI-FAPI-04 showed significantly higher tumor uptake and retention over [68Ga]Ga-DOTA-FAPI-04, with particularly enhanced visualization of hypoxic lesions, suggesting that hypoxia-sensitive moiety may play an important role in detection of tumors. Further study of [177Lu]Lu-DOTA-NI-FAPI-04 in humans is warranted to explore its clinical applications. URL OF REGISTRY: https://clinicaltrials.gov/study/NCT06688305 . TRIAL REGISTRATION: ClinicalTrials.gov, NCT06688305, Registered 14 November 2024, retrospectively registered.
引用
- Zang J, Cheng H, Luo Y, et al. First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia. Eur J Nucl Med Mol Imaging. 2025. PMID: 41168395. doi:10.1007/s00259-025-07625-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。